HK1207861A1 - Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 - Google Patents
Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1Info
- Publication number
- HK1207861A1 HK1207861A1 HK15108514.3A HK15108514A HK1207861A1 HK 1207861 A1 HK1207861 A1 HK 1207861A1 HK 15108514 A HK15108514 A HK 15108514A HK 1207861 A1 HK1207861 A1 HK 1207861A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bub1
- cycloalkenopyrazoles
- cancer
- substituted
- treatment
- Prior art date
Links
- 101150076596 bub-1 gene Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167690 | 2012-05-11 | ||
| PCT/EP2013/059666 WO2013167698A1 (fr) | 2012-05-11 | 2013-05-08 | Cycloalcénopyrazoles substitués en tant qu'inhibiteurs de bub1 pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207861A1 true HK1207861A1 (en) | 2016-02-12 |
Family
ID=48407563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15108514.3A HK1207861A1 (en) | 2012-05-11 | 2015-09-01 | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150141372A1 (fr) |
| EP (1) | EP2847180B1 (fr) |
| JP (1) | JP2015520143A (fr) |
| CN (1) | CN104411701B (fr) |
| CA (1) | CA2872933A1 (fr) |
| ES (1) | ES2620316T3 (fr) |
| HK (1) | HK1207861A1 (fr) |
| WO (1) | WO2013167698A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| JP2016514718A (ja) * | 2013-03-21 | 2016-05-23 | バイエル ファーマ アクチエンゲゼルシャフト | ３−ヘテロアリール置換インダゾール類 |
| CA2907730A1 (fr) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Indazoles substitues par diaminoheteroaryle |
| EP2976335A1 (fr) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Indazoles substitués par hétéroaryle |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CA2916103A1 (fr) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Pyrazoles a substitution diaminoheteroaryle |
| CA2916116A1 (fr) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Benzylpyrazoles substitues |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| WO2015193339A1 (fr) * | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino -1,5,6,7-tétrahydro-4 h-indol-4-ones |
| CN107001331A (zh) | 2014-09-19 | 2017-08-01 | 拜耳制药股份公司 | 作为bub1抑制剂的苄基取代的吲唑 |
| JP6704398B2 (ja) | 2015-01-28 | 2020-06-03 | バイエル ファーマ アクチエンゲゼルシャフト | ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体 |
| JP2018522847A (ja) * | 2015-06-17 | 2018-08-16 | バイエル ファーマ アクチエンゲゼルシャフト | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| CA2994596A1 (fr) | 2015-08-05 | 2017-02-09 | Bayer Pharma Aktiengesellschaft | 1h-pyrrol-3-amines |
| WO2017102649A1 (fr) * | 2015-12-16 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Hétéro-1,5,6,7-tétrahydro-4h-indol-4-ones |
| WO2017148995A1 (fr) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles possédant une activité d'inhibition de la kinase bub1 |
| WO2017157992A1 (fr) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Pyrazoles annelés utilisés en tant qu'inhibiteurs de kinase bub1 pour le traitement de troubles prolifératifs |
| WO2017157991A1 (fr) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles et 1-alkyl-indazoles utilisés en tant qu'inhibiteurs de bub1 pour le traitement de maladies hyperprolifératives |
| WO2018122168A1 (fr) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp |
| WO2018158175A1 (fr) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de bub1 |
| WO2018206547A1 (fr) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de bub1 et d'atr |
| WO2018215282A1 (fr) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combinaison d'inhibiteurs de bub1 et de pi3k |
| IL301532A (en) | 2020-09-23 | 2023-05-01 | Scorpion Therapeutics Inc | History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment |
| WO2022072645A2 (fr) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Méthodes de traitement du cancer |
| WO2022072634A1 (fr) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Composés bicycliques destinés à être utilisés dans le traitement du cancer |
| BR112023006531A2 (pt) | 2020-10-09 | 2023-10-03 | Scorpion Therapeutics Inc | Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer |
| WO2022094271A1 (fr) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Méthodes de traitement du cancer |
| WO2022098992A1 (fr) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Utilisation de composés macrocycliques dans des méthodes de traitement de cancer |
| WO2022197913A1 (fr) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Dérivés bicycliques pouvant être utilisés pour traiter le cancer |
| WO2023173083A1 (fr) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Dérivés de tétrahydroindole utilisés en tant qu'inhibiteurs d'egfr et/ou de her2 utiles pour le traitement du cancer |
| EP4293019A1 (fr) * | 2022-06-13 | 2023-12-20 | Netherlands Translational Research Center Holding B.V. | (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles 4-substitués comme inhibiteurs de bub1 utiles pour le traitement des cancers |
| CN116036121B (zh) * | 2022-12-16 | 2024-10-18 | 福州载基生物科技有限公司 | 人bub1基因在制备抗肿瘤药物中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| EP1254105A1 (fr) | 2000-02-10 | 2002-11-06 | Lonza AG | Procede de fabrication de nitriles d'acide alcoxy-malonique |
| EP1351691A4 (fr) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee |
| US20050209252A1 (en) * | 2002-03-29 | 2005-09-22 | Che-Ming Teng | Cancer treatment |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| WO2008007113A2 (fr) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
| US20130178475A1 (en) * | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| EP2594270A3 (fr) * | 2011-11-18 | 2013-07-31 | BIP Patents | Utilisation de stimulateurs de la sGC ou d'activateurs de la sGC, seuls et en combinaison avec des inhibiteurs de PDE5 pour le traitement de la sclérose systémique (Ssc) |
-
2013
- 2013-05-08 CA CA2872933A patent/CA2872933A1/fr not_active Abandoned
- 2013-05-08 WO PCT/EP2013/059666 patent/WO2013167698A1/fr active Application Filing
- 2013-05-08 JP JP2015510822A patent/JP2015520143A/ja not_active Ceased
- 2013-05-08 EP EP13721755.0A patent/EP2847180B1/fr not_active Not-in-force
- 2013-05-08 ES ES13721755.0T patent/ES2620316T3/es active Active
- 2013-05-08 CN CN201380036066.XA patent/CN104411701B/zh not_active Expired - Fee Related
- 2013-05-08 US US14/400,315 patent/US20150141372A1/en active Granted
-
2015
- 2015-09-01 HK HK15108514.3A patent/HK1207861A1/xx unknown
-
2017
- 2017-03-08 US US15/453,679 patent/US20170275267A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2847180B1 (fr) | 2017-01-04 |
| JP2015520143A (ja) | 2015-07-16 |
| US20170275267A1 (en) | 2017-09-28 |
| US20150141372A1 (en) | 2015-05-21 |
| ES2620316T3 (es) | 2017-06-28 |
| CN104411701A (zh) | 2015-03-11 |
| WO2013167698A1 (fr) | 2013-11-14 |
| CA2872933A1 (fr) | 2013-11-14 |
| CN104411701B (zh) | 2017-01-18 |
| EP2847180A1 (fr) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
| HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
| PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
| HK1206338A1 (en) | Pyrimidine compounds for the treatment of cancer | |
| EP2964028A4 (fr) | Composés pour le traitement du cancer | |
| PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| HUE045461T2 (hu) | Gyógyászati készítmény rák kezelésére | |
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| EP2925752A4 (fr) | Composés à base de pyrimidine utilisables à des fins de traitement du cancer | |
| HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
| HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| EP2897607A4 (fr) | Inhibiteurs de bêta-hydrolase pour le traitement du cancer | |
| GB201214877D0 (en) | Compounds for treatments of tumors | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| HK1206633A1 (en) | Composition for treatment of warts | |
| IL237229A0 (en) | Methods of treating cancer using lipoplatin | |
| IL231448A0 (en) | Phosphatidylinositol 3-kinase inhibitors for cancer treatment | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer | |
| HK1200094A1 (en) | Use of immunomodulators for the treatment of cancer | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer |